1407 related articles for article (PubMed ID: 31214177)
41. Natural killer cell-related anti-tumour adoptive cell immunotherapy.
Qi Y; Li Y; Wang H; Wang A; Liu X; Liang Z; Gao Y; Wei L
J Cell Mol Med; 2024 Jun; 28(11):e18362. PubMed ID: 38837666
[TBL] [Abstract][Full Text] [Related]
42. The Next Generation of Cellular Immunotherapy: Chimeric Antigen Receptor-Natural Killer Cells.
Moscarelli J; Zahavi D; Maynard R; Weiner LM
Transplant Cell Ther; 2022 Oct; 28(10):650-656. PubMed ID: 35788086
[TBL] [Abstract][Full Text] [Related]
43. Enhancement of antitumor potency of extracellular vesicles derived from natural killer cells by IL-15 priming.
Zhu L; Kalimuthu S; Oh JM; Gangadaran P; Baek SH; Jeong SY; Lee SW; Lee J; Ahn BC
Biomaterials; 2019 Jan; 190-191():38-50. PubMed ID: 30391801
[TBL] [Abstract][Full Text] [Related]
44. CAR-expressing NK cells for cancer therapy: a new hope.
Xia J; Minamino S; Kuwabara K
Biosci Trends; 2020 Nov; 14(5):354-359. PubMed ID: 32893255
[TBL] [Abstract][Full Text] [Related]
45. CAR-NK for tumor immunotherapy: Clinical transformation and future prospects.
Wang W; Jiang J; Wu C
Cancer Lett; 2020 Mar; 472():175-180. PubMed ID: 31790761
[TBL] [Abstract][Full Text] [Related]
46. Natural Killer Cells: Angels and Devils for Immunotherapy.
Martín-Antonio B; Suñe G; Perez-Amill L; Castella M; Urbano-Ispizua A
Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28850071
[TBL] [Abstract][Full Text] [Related]
47. Preclinical studies of chimeric antigen receptor-modified natural killer cells in cancer immunotherapy: a review.
Hosseini M; Habibi Z; Hosseini N; Abdoli S; Rezaei N
Expert Opin Biol Ther; 2022 Mar; 22(3):349-366. PubMed ID: 34541989
[TBL] [Abstract][Full Text] [Related]
48. Chimeric antigen receptor engineered innate immune cells in cancer immunotherapy.
Lin C; Zhang J
Sci China Life Sci; 2019 May; 62(5):633-639. PubMed ID: 30796720
[TBL] [Abstract][Full Text] [Related]
49. Exploring the NK cell platform for cancer immunotherapy.
Myers JA; Miller JS
Nat Rev Clin Oncol; 2021 Feb; 18(2):85-100. PubMed ID: 32934330
[TBL] [Abstract][Full Text] [Related]
50. Current progress in cancer immunotherapy based on natural killer cells.
Bagheri Y; Barati A; Aghebati-Maleki A; Aghebati-Maleki L; Yousefi M
Cell Biol Int; 2021 Jan; 45(1):2-17. PubMed ID: 32910474
[TBL] [Abstract][Full Text] [Related]
51. Natural killer cell engineering - a new hope for cancer immunotherapy.
Lin CY; Gobius I; Souza-Fonseca-Guimaraes F
Semin Hematol; 2020 Oct; 57(4):194-200. PubMed ID: 33256912
[TBL] [Abstract][Full Text] [Related]
52. iPSC-Derived Natural Killer Cell Therapies - Expansion and Targeting.
Goldenson BH; Hor P; Kaufman DS
Front Immunol; 2022; 13():841107. PubMed ID: 35185932
[TBL] [Abstract][Full Text] [Related]
53. Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells.
Saetersmoen ML; Hammer Q; Valamehr B; Kaufman DS; Malmberg KJ
Semin Immunopathol; 2019 Jan; 41(1):59-68. PubMed ID: 30361801
[TBL] [Abstract][Full Text] [Related]
54. Proteome Analysis of Human Natural Killer Cell Derived Extracellular Vesicles for Identification of Anticancer Effectors.
Choi JW; Lim S; Kang JH; Hwang SH; Hwang KC; Kim SW; Lee S
Molecules; 2020 Nov; 25(21):. PubMed ID: 33182448
[TBL] [Abstract][Full Text] [Related]
55. Natural Killer Cell-Derived Extracellular Vesicles: Novel Players in Cancer Immunotherapy.
Wu F; Xie M; Hun M; She Z; Li C; Luo S; Chen X; Wan W; Wen C; Tian J
Front Immunol; 2021; 12():658698. PubMed ID: 34093547
[TBL] [Abstract][Full Text] [Related]
56. Natural Killer Cell-Derived Vesicular miRNAs: A New Anticancer Approach?
Fabbri M
Cancer Res; 2020 Jan; 80(1):17-22. PubMed ID: 31672842
[TBL] [Abstract][Full Text] [Related]
57. IPSC-derived CAR-NK cells for cancer immunotherapy.
Lin X; Sun Y; Dong X; Liu Z; Sugimura R; Xie G
Biomed Pharmacother; 2023 Sep; 165():115123. PubMed ID: 37406511
[TBL] [Abstract][Full Text] [Related]
58. Precision immunotherapy for cholangiocarcinoma: Pioneering the use of human-derived anti-cMET single chain variable fragment in anti-cMET chimeric antigen receptor (CAR) NK cells.
Chiawpanit C; Wathikthinnakorn M; Sawasdee N; Phanthaphol N; Sujjitjoon J; Junking M; Yamabhai M; Panaampon J; Yenchitsomanus PT; Panya A
Int Immunopharmacol; 2024 Jul; 136():112273. PubMed ID: 38810311
[TBL] [Abstract][Full Text] [Related]
59. Natural killer cell-based immunotherapy for acute myeloid leukemia.
Xu J; Niu T
J Hematol Oncol; 2020 Dec; 13(1):167. PubMed ID: 33287858
[TBL] [Abstract][Full Text] [Related]
60. NK Cells Equipped With a Chimeric Antigen Receptor That Overcomes Inhibition by HLA Class I for Adoptive Transfer of CAR-NK Cells.
Zhuang X; Long EO
Front Immunol; 2022; 13():840844. PubMed ID: 35585985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
